GLSH Stock Overview
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Gelesis Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.012 |
| 52 Week High | US$0.55 |
| 52 Week Low | US$0.0082 |
| Beta | 1.96 |
| 11 Month Change | -75.83% |
| 3 Month Change | -76.71% |
| 1 Year Change | -96.89% |
| 33 Year Change | -99.88% |
| 5 Year Change | n/a |
| Change since IPO | -99.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| GLSH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.8% | 4.0% | 2.0% |
| 1Y | -96.9% | 18.0% | 32.4% |
Return vs Industry: GLSH underperformed the US Biotechs industry which returned -3.5% over the past year.
Return vs Market: GLSH underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| GLSH volatility | |
|---|---|
| GLSH Average Weekly Movement | 30.7% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GLSH's share price has been volatile over the past 3 months.
Volatility Over Time: GLSH's weekly volatility has decreased from 46% to 31% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 93 | Yishai Zohar | www.gelesis.com |
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation.
Gelesis Holdings, Inc. Fundamentals Summary
| GLSH fundamental statistics | |
|---|---|
| Market cap | US$850.69k |
| Earnings (TTM) | -US$51.67m |
| Revenue (TTM) | US$12.14m |
0.1x
P/S Ratio0.0x
P/E RatioIs GLSH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLSH income statement (TTM) | |
|---|---|
| Revenue | US$12.14m |
| Cost of Revenue | US$19.59m |
| Gross Profit | -US$7.45m |
| Other Expenses | US$44.21m |
| Earnings | -US$51.67m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.70 |
| Gross Margin | -61.40% |
| Net Profit Margin | -425.58% |
| Debt/Equity Ratio | -325.5% |
How did GLSH perform over the long term?
See historical performance and comparison